-
1
-
-
38849140635
-
-
U.S. Patent 4097487
-
(a) Murakami, K.; Takahashi, M.; Hirata, Y.; Takashima, M.; Iwanami, S.; Hasegawa, O.; Nozaki, Y.; Tashikawa, S.; Takeda, M.; Usuda, S. U.S. Patent 4097487, 1978.
-
(1978)
-
-
Murakami, K.1
Takahashi, M.2
Hirata, Y.3
Takashima, M.4
Iwanami, S.5
Hasegawa, O.6
Nozaki, Y.7
Tashikawa, S.8
Takeda, M.9
Usuda, S.10
-
3
-
-
0019725606
-
-
(c) Iwanami, S.; Takashima, H.; Hirata, Y.; Hasagewa, O.; Usuda, S. J. Med. Chem. 1981, 24, 1224.
-
(1981)
J. Med. Chem
, vol.24
, pp. 1224
-
-
Iwanami, S.1
Takashima, H.2
Hirata, Y.3
Hasagewa, O.4
Usuda, S.5
-
4
-
-
0020330967
-
-
(a) Furuya, T.; Iwanami, S.; Takenaka, A.; Sasada, Y. Bull. Chem. Soc. Jpn 1982, 55, 2321.
-
(1982)
Bull. Chem. Soc. Jpn
, vol.55
, pp. 2321
-
-
Furuya, T.1
Iwanami, S.2
Takenaka, A.3
Sasada, Y.4
-
5
-
-
0019924569
-
-
(b) Yamamoto, M.; Usuda, S.; Tachikawa, S.; Maeno, H. Neurophamacology 1982, 21, 945.
-
(1982)
Neurophamacology
, vol.21
, pp. 945
-
-
Yamamoto, M.1
Usuda, S.2
Tachikawa, S.3
Maeno, H.4
-
6
-
-
0031032302
-
-
Huang, P. Q.; Wang, S. L.; Zheng, H.; Fei, X. S. Tetrahedron Lett. 1997, 38, 271.
-
(1997)
Tetrahedron Lett
, vol.38
, pp. 271
-
-
Huang, P.Q.1
Wang, S.L.2
Zheng, H.3
Fei, X.S.4
-
7
-
-
34250625513
-
-
Shibugushi, T.; Mihara, H.; Kuramochi, A.; Ohshima, T.; Shibasaki, M. Chem. Asian J. 2007, 2, 794.
-
(2007)
Chem. Asian J
, vol.2
, pp. 794
-
-
Shibugushi, T.1
Mihara, H.2
Kuramochi, A.3
Ohshima, T.4
Shibasaki, M.5
-
8
-
-
34547198945
-
-
Hoang, C. T.; Alezra, V.; Guillot, R.; Kouklovsky, C. Org. Lett. 2007, 9, 2521.
-
(2007)
Org. Lett
, vol.9
, pp. 2521
-
-
Hoang, C.T.1
Alezra, V.2
Guillot, R.3
Kouklovsky, C.4
-
9
-
-
33745193911
-
-
and references cited therein, For the synthesis and properties of 3-aminopyrrolidines, see: a
-
For the synthesis and properties of 3-aminopyrrolidines, see: (a) Davies, S. G.; Garner, A. C.; Goddard, E. C.; Kruchinin, D.; Roberts, P. M.; Rodriguez-Solla, H.; Smith, A. D. Chem. Commun. 2006, 2664 and references cited therein,
-
(2006)
Chem. Commun
, pp. 2664
-
-
Davies, S.G.1
Garner, A.C.2
Goddard, E.C.3
Kruchinin, D.4
Roberts, P.M.5
Rodriguez-Solla, H.6
Smith, A.D.7
-
10
-
-
30144437267
-
-
See also
-
(b) See also: Vargas-Sanchez, M.; Couty, F.; Evano, G.; Prim, D.; Marrot, J. Org. Lett. 2005, 7, 5861.
-
(2005)
Org. Lett
, vol.7
, pp. 5861
-
-
Vargas-Sanchez, M.1
Couty, F.2
Evano, G.3
Prim, D.4
Marrot, J.5
-
11
-
-
38849102010
-
-
The enantiomeric purity of 8 was checked by HPLC analysis on a chiral column and comparison with a racemic standard (prepared according to the same synthetic sequence from racemic alanine) and was found to be >99%.
-
The enantiomeric purity of 8 was checked by HPLC analysis on a chiral column and comparison with a racemic standard (prepared according to the same synthetic sequence from racemic alanine) and was found to be >99%.
-
-
-
-
12
-
-
38849191442
-
-
Since there is a slight difference in the optical rotation of synthetic nemonapride 1 and literature data, the enantiomeric purity of 1 was checked by HPLC analysis on a chiral column with comparison to a racemic standard (prepared according to the same synthetic sequence from racemic alanine) and was found to be >99%.
-
Since there is a slight difference in the optical rotation of synthetic nemonapride 1 and literature data, the enantiomeric purity of 1 was checked by HPLC analysis on a chiral column with comparison to a racemic standard (prepared according to the same synthetic sequence from racemic alanine) and was found to be >99%.
-
-
-
|